Please login to the form below

Not currently logged in
Email:
Password:

diffuse large B-cell lymphoma

This page shows the latest diffuse large B-cell lymphoma news and features for those working in and with pharma, biotech and healthcare.

Imbruvica gains expanded use in Europe

Imbruvica gains expanded use in Europe

It is also approved for use in mantle cell lymphoma (MCL) for the treatment of adult patients who have relapsed or refractory MCL. ... B-cell lymphoma.

Latest news

  • Triplet approvals for myeloma boost Celgene in Q2 Triplet approvals for myeloma boost Celgene in Q2

    Abraxane is enjoying a sales surge thanks to its use in combination with cancer immunotherapies in indications like non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC), according ... CAR-T therapy liso-cel (lisocabtagene maraleucel

  • Roche’s Polivy gets FDA okay for lymphoma chemo-immunotherapy Roche’s Polivy gets FDA okay for lymphoma chemo-immunotherapy

    First-in-class antibody drug conjugate. The FDA has approved Roche’s Polivy as part of the first chemo-immunotherapy combination for a B-cell lymphoma. ... The antibody-drug conjugate has been cleared for use alongside the chemotherapy bendamustine and

  • J&J takes option on Genmab follow-up to Darzalex J&J takes option on Genmab follow-up to Darzalex

    Johnson &Johnson’s longstanding alliance with Genmab has already produced one blockbuster drug for lymphoma – Darzalex – and it is now eyeing a follow-up candidate. ... Under the terms of the deal Genmab will develop HexaBody-CD38 for multiple

  • Regeneron's bispecific for lymphoma works in CAR-T failures Regeneron's bispecific for lymphoma works in CAR-T failures

    rates in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). ... Roche’s mosunetuzumab candidate showed activity in relapsed/refractory B-cell indolent and aggressive NHL in a phase 1/2 trial

  • AZ’s Calquence threatens Imbruvica with new leukaemia data AZ’s Calquence threatens Imbruvica with new leukaemia data

    Calquence is currently a minnow in comparison, making $62m last year as a treatment for mantle cell lymphoma (MCL), its first and only approved indication at the moment. ... AZ has a host of studies testing its BTK inhibitor in diseases such as multiple

More from news
Approximately 1 fully matching, plus 71 partially matching documents found.

Latest Intelligence

  • 25 Women Leaders in UK Healthcare (part 2) 25 Women Leaders in UK Healthcare (part 2)

    13. SORAYA BEKKALI. Gene therapy pioneer. Cell and gene therapy is definitely the most exciting development in biopharma research, promising breakthroughs and even cures for previously untreatable diseases. ... It has brought to market not one but two

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    antigen receptor T-cell (CAR-T) therapies from Novartis and Gilead gained regulatory approval in 2017 for acute lymphoblastic leukaemia (ALL) and diffuse large B-cell lymphoma (DLBCL) after showing remarkable ... Celgene and Juno hope to crash the party

  • Deal Watch January 2018

    pivotal trial for relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL).  According to Celgene's press release, regulatory approval for JCAR017 in the US is anticipated in 2019 with ... DLBCL = diffuse large B-cell lymphoma. BTK = Bruton's

  • Pharma deals in April 2015 Pharma deals in April 2015

    MEDI4736 is an immune checkpoint inhibitor which is targeted against programmed cell death (PD-L1). ... its SAR3419, an antibody-drug conjugate designed to treat diffuse large B-cell lymphoma (DLBCL) and other blood cancers.

  • Pharma deals during June 2014 Pharma deals during June 2014

    a deal with NanoString Technologies for the development of a companion diagnostic assay to support the development of Revlimid for treatment of Diffuse Large B-Cell Lymphoma at a more modest

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics